SII Seeks Inclusion of Covid Jab Covovax in CoWIN Portal as Heterologous Booster Dose for Adults

0

Last Updated: January 18, 2023, 18:51 IST

National Technical Advisory Group on Immunisation (NTAGI) is likely to hold a meeting soon to decide on the matter.

(File photo: PTI)

National Technical Advisory Group on Immunisation (NTAGI) is more likely to maintain a gathering quickly to resolve on the matter.

(File picture: PTI)

The Drug Controller General of India (DCGI) on January 16 accepted market authorisation for Covovax as a heterologous booster dose for adults who’ve been administered two doses of both Covishield or Covaxin

Serum Institute of India has written to the Union Health Ministry looking for the inclusion of its Covid vaccine Covovax in the CoWIN portal as a heterologous booster dose for adults, official sources mentioned on Wednesday.

The letter was written by Prakash Kumar Singh, Director, Government and Regulatory Affairs at Serum Institute of India (SII), they mentioned.

National Technical Advisory Group on Immunisation (NTAGI) is more likely to maintain a gathering quickly to resolve on the matter.

The Drug Controller General of India (DCGI) on January 16 accepted market authorisation for Covovax as a heterologous booster dose for adults who’ve been administered two doses of both Covishield or Covaxin.

Its approval was based mostly on suggestions by the topic professional committee (SEC) of the Central Drugs Standard Control Organisation.

The DCGI accepted Covovax for restricted use in emergency conditions in adults on December 28, 2021, in the 12-17 age group on March 9, 2022, and in addition in kids aged seven to 11 years on June 28 final 12 months topic to sure circumstances.

Covovax is manufactured by expertise switch from Novavax.

It has been accepted by the European Medicines Agency for conditional advertising authorization and was granted emergency-use itemizing by the World Health Organization (WHO) on December 17, 2021.

In August 2020, US-based vaccine maker Novavax Inc. had earlier introduced a licence settlement with the SII for the event and commercialization of NVX-CoV2373, its COVID-19 vaccine candidate in India and low-and-middle-income nations.

Read all of the Latest India News right here

(This story has not been edited by News18 workers and is revealed from a syndicated information company feed)

Source hyperlink

LEAVE A REPLY

Please enter your comment!
Please enter your name here